: Avidity’s stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments

Avidity Biosciences Inc. said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments.

The news sent Avidity’s stock RNA up 30.5% in premarket trade.

Avidity will receive a $60 million…

Master your money.

Subscribe to MarketWatch.

Get this article and all of MarketWatch.

Access from any device. Anywhere. Anytime.


Subscribe Now

This post was originally published on MarketWatch

Share your love